Heres another one. Servier paid $1.8 Billion to acquire it. Some...

Heres another one. Servier paid $1.8 Billion to acquire it. Some familiar names involved in the trial.

https://www.uclahealth.org/news/new-drug-delays-progression-glioma-deadly-brain-cancer

https://www.cancer.gov/news-events/cancer-currents-blog/2023/vorasidenib-low-grade-glioma-idh-mutations

https://www.biospace.com/article/asco-french-pharma-serves-up-win-for-low-grade-glioma-patients-/

"Servier, a private French biopharma company, entered the U.S. market nearly five years ago, setting up shop in Boston in 2019 after acquiring Shire’s oncology business for $2.4 billion in 2018. The company made another big splash in December 2021, shelling out $1.8 billion to acquire Agios Pharmaceuticals’ oncology business.Vorasidenib was the lead asset in the package, coming over to the French pharma along with AG-270, an adenosyltransferase 2a (MAT2A) inhibitor being developed for non-small cell lung cancer (NSCLC) and pancreatic cancer, and AG-636, which inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme implicated in tumor progression."

"This particular type of glioma afflicts approximately 4,000 people in the U.S., Glenn Lesser, a neuro-oncologist and professor at the Wake Forest University School of Medicine, told STAT News. Lesser, who was not involved in the study, called the results “clinically very significant and important.”"